0
Deep & Emerging Tech·July 27, 2026·1 min read

The FDA just picked its first company to sell an unauthorised device to Medicare patients

Share

The FDA’s TEMPO pilot naming Dexcom as its first participant opens a path for digital health devices to reach Medicare patients before full authorization—under enforcement discretion. If you build regulated digital health, this is a new go-to-market vector, but it also raises the bar on real-world evidence and post-market surveillance from day one.